Alphatec (ATEC) Stock May Look Discounted On Cash Flow And Sales
Alphatec Holdings stock has had a difficult year so far, with the share price down 49% year to date, yet several valuation checks suggest the current market price may sit well below what the underlying cash flows could justify.
- The year to date decline of 49% leaves the stock trading far below where it started 2026, which puts current pricing under closer scrutiny for potential mispricing.
- Future cash generation from Alphatec Holdings spinal surgery platform can support the current equity value if execution on growth and margins continues. Any setback in turning that revenue into durable free cash flow is a key risk for the valuation case.
- 5 out of 6 valuation checks suggest Alphatec Holdings leans cheap, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to an undervalued profile.
The issue now is whether Alphatec Holdings current price really offers a meaningful discount to intrinsic value, or if the slump in the share price better reflects the underlying business risks.
Pressure test Alphatec Holdings against a wider peer group by scanning our hand picked list of 31 high quality undervalued stocks that also screen cheaply on cash flows and fundamentals.
Is Alphatec Holdings Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here uses projected free cash flows to equity and then discounts them back to today. For Alphatec Holdings, the latest twelve month free cash flow is a loss of about $35 million, so the valuation in this model depends on a recovery in cash generation rather than current profitability.
Analyst projections in the model assume growing free cash flow over the next decade, which feeds into an estimated intrinsic value of about $20.59 per share. Compared with the current share price, that DCF output indicates the stock is trading at roughly a 48.6% discount, suggesting the market is assigning a lower value to the future cash flow stream than this model implies.
Under these cash flow assumptions, Alphatec Holdings stock currently appears undervalued in this DCF framework.
Our Discounted Cash Flow (DCF) analysis suggests Alphatec Holdings is undervalued by 48.6%. Track this in your watchlist or portfolio, or discover 31 more high quality undervalued stocks.
Is Alphatec Holdings Still Cheap on Sales?
P/S works well for Alphatec Holdings because investors are mainly paying for spinal surgery revenue today rather than current earnings.
The stock trades on a P/S of about 2.0x, compared with roughly 2.9x for the wider Medical Equipment industry and about 5.9x across the closer peer set. A P/S ratio of about 3.5x has been estimated as fair based on Alphatec Holdings specific profile. This is higher than where the shares change hands right now.
That gap suggests the market is valuing each dollar of Alphatec Holdings sales at a discount to what this framework implies could be reasonable for a business in its segment and risk bucket.
On this revenue multiple, Alphatec Holdings stock appears undervalued relative to both its fair P/S estimate and peer benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Alphatec Holdings Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Alphatec Holdings pick up where the valuation work leaves off and spell out which combinations of growth, margins and earnings would need to hold for Alphatec Holdings' share price to be worth materially more or less than it is today on the market. They sit on Simply Wall St's Community page and turn each ratio or model output into a concrete future path, so you can follow whether that underlying story stays on track over time.
One of the top community narratives on Alphatec Holdings: 12% undervalued
"Shifting industry dynamics and cost pressures threaten Alphatec's pricing power, revenue growth, and ability to maintain strong margins as lower-cost alternatives gain traction..."
Read one of the top narratives on Alphatec Holdings
Do you think there's more to the story for Alphatec Holdings? Head over to our Community to see what others are saying!
The Bottom Line
For Alphatec Holdings, both the Discounted Cash Flow (DCF) intrinsic value estimate and the sales multiple work point in the same direction, suggesting the current valuation leans undervalued rather than stretched. The DCF framework implies the share price sits well below the modelled worth of future cash flows, while the P/S comparison indicates the market prices Alphatec's revenue at a discount to peers and to its own fair ratio estimate.
Everything now hinges on a single question: Can Alphatec turn its spinal surgery platform into consistent free cash flow that matches those assumptions, or is the current discount compensation for execution risk that proves harder to overcome than the models imply?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com